Iparomlimab (Tuvonralimab, QL1706)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Iparomlimab (Tuvonralimab, QL1706), covering 2025-04-17 to 2025-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma [Phase 2]